Drugs Made In America Acquisition (DMIIR) Liabilities and Shareholders Equity (2024 - 2025)

Drugs Made In America Acquisition (DMIIR) reported Liabilities and Shareholders Equity of $505.0 million for Q4 2025, up 365643.31% year-over-year from N/an in Q4 2024, and up 0.79% on a QoQ basis from $501.0 million in Q3 2025.

Drugs Made In America Acquisition (DMIIR) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $505.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 474.42 Mn
2 Berto Acquisition 316.66 Mn 316.66 Mn - 311.76 Mn
3 Centurion Acquisition 311.94 Mn 311.94 Mn - 310.95 Mn
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn - 310.55 Mn
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn - 366.18 Mn
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn - 289.04 Mn
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn - 272.82 Mn
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn - 286.39 Mn
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn - 262.39 Mn
10 Drugs Made In America Acquisition - - - 504.96 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 504.96 Mn
Sep 30, 2025 501.01 Mn
Dec 31, 2024 138,064.00